<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04121507</url>
  </required_header>
  <id_info>
    <org_study_id>ASTRAL / GLA-aNHL-R1</org_study_id>
    <nct_id>NCT04121507</nct_id>
  </id_info>
  <brief_title>ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy</brief_title>
  <official_title>A Prospective Phase II Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy Followed by Allogeneic Stem Cell Transplantation as Treatment of Primary Progressive and Relapsed Aggressive Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GWT-TUD GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GWT-TUD GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective Phase II clinical study to assess the efficacy and toxicity of high dose
      chemotherapy (HDT) followed by allogeneic stem cell transplantation (allo- or autoSCT) as
      treatment of primary progressive and relapsed aggressive Non-Hodgkin Lymphoma (NHL) - ASTRAL
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a clinical study to assess the treatment (efficacy and toxicity) with a high dosed
      chemotherapy followed by stem cell transplantation in patients suffering from primary
      progressive and relapsed aggressive Non-Hodgkin Lymphoma (NHL)

      After end of the active study phase, patients will receive further standard medical care at
      the discretion of the treating physician. The clinical consultants will provide advice on
      further treatment if requested.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 24, 2019</start_date>
  <completion_date type="Anticipated">March 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of efficacy variables, Rate of Progression free survival (PFS)</measure>
    <time_frame>1 year after SCT</time_frame>
    <description>To compare a defined high dose therapy (HDT) with study medication followed by alloSCT lead to treatment results in terms of PFS, that are better than results obtained with high-dose therapy and autoSCT in a comparable Patient Population ( historical data).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of efficacy variables, Rate of complete remissions (CR)</measure>
    <time_frame>1 year after stem cell transplantation (SCT)</time_frame>
    <description>Number of complete remissions divided by the number of patients (CR),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of efficacy variables, Rate of partial remissions (PR)</measure>
    <time_frame>1 year after SCT</time_frame>
    <description>Number of partial remissions divided by the number of patients (PR);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of efficacy variables, Rate of complete and partial remissions (ORR)</measure>
    <time_frame>1 year after SCT</time_frame>
    <description>Number of complete and partial remissions divided by the number of patients (ORR);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of efficacy variables, Rate of progressive diseases (PD)</measure>
    <time_frame>1 year after SCT</time_frame>
    <description>Number of progressive diseases after SCT divided by the number of patients (PD);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of efficacy variables, Rate of relapse (RR)</measure>
    <time_frame>1 year after SCT</time_frame>
    <description>safety item</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of efficacy variables, Rate of treatment-related mortality</measure>
    <time_frame>1 year after SCT</time_frame>
    <description>treatment-related death divided by the number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of event free survival at 1 year (EFS)</measure>
    <time_frame>1 year after SCT</time_frame>
    <description>safety item</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of efficacy variables, Rate of overall survival at 1 year (OS)</measure>
    <time_frame>1 year after SCT</time_frame>
    <description>safety item</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of efficacy variables, Rate of non-relapse mortality (NRM)</measure>
    <time_frame>1year after SCT</time_frame>
    <description>safety item</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of efficacy variables, Causes of death</measure>
    <time_frame>1year after SCT</time_frame>
    <description>safety item</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of efficacy variables, Incidence and severity of acute and chronic graft versus host disease (GvHD);</measure>
    <time_frame>until the last Follow-Up Visit ( 1-2 Year after SCT)</time_frame>
    <description>safety item</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of efficacy variables, Adverse events (AEs) grade 3 and 4</measure>
    <time_frame>until about day 100 after SCT.</time_frame>
    <description>safety item</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of efficacy variables, Serious adverse events (SAEs)</measure>
    <time_frame>until about day 100 after SCT.</time_frame>
    <description>safety item</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of number of blood cells</measure>
    <time_frame>1year after SCT</time_frame>
    <description>recovery of White blood cells and platelets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of efficacy variables, Rate of infections</measure>
    <time_frame>1year after SCT</time_frame>
    <description>safety item</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Aggressive Non-hodgkin Lymphoma (aNHL)</condition>
  <condition>Lymphoma, B-Cell</condition>
  <condition>Lymphoma, T-Cell</condition>
  <arm_group>
    <arm_group_label>alloSCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>defined high-dose chemotherapy (HDT) followed by allogeneic stem cell transplantation (alloSCT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose chemotherapy before allogeneic stem cell transplantation (alloSCT)</intervention_name>
    <description>High-dose therapy (HDT) prior to alloSCT will consist of FTC</description>
    <arm_group_label>alloSCT</arm_group_label>
    <other_name>fludarabine, thiotepa ,cyclophosphamide (FTC)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone marrow histology</intervention_name>
    <description>Bone marrow histology at staging and restaging is only mandatory if the bone marrow was initially involved</description>
    <arm_group_label>alloSCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>clinical and laboratory parameters</intervention_name>
    <description>During staging and restaging examinations, all clinical and laboratory parameters relevant for therapy.</description>
    <arm_group_label>alloSCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PET-CT or CT</intervention_name>
    <description>Metabolic CR in a PET-CT scan after the last cycle of therapy prior to planned SCT. Consists preferably of a PET-CT or a CT scan according to local practice and other appropriate diagnostic procedures with respect to the sites of primary involvement.</description>
    <arm_group_label>alloSCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must fulfill all of the following criteria to be included in this trial:

          1. Provision of written informed consent and specifically the consent to the collection
             and processing of health-related data

          2. Age: 18 years and older

          3. Gender: Male and female patients

          4. Histology

          5. Diagnosis of relapsed or primary progressive aggressive B- or T-cell lymphoma
             including:

               1. B-Cell non-hodgkin lymphoma (B-NHL) or

               2. T-Cell non-hodgkin lymphoma (T-NHL):

          6. Staging at relapse or progression (data should not be older than 4 weeks):

          7. Staging after 2 or 3 cycles of salvage treatment:

          8. Donor availability:

          9. Females of childbearing potential (FCBP) must:

               -  Understand the potential teratogenic risk to the unborn child

               -  Understand the need and agree to utilize two reliable forms of contraception

               -  Understand and agree to inform the investigator if a change or stop of method of
                  contraception is needed

               -  Be capable of complying with effective contraceptive measures

               -  Be informed and understand the potential consequences of pregnancy and the need
                  to notify her study doctor immediately if there is a risk of pregnancy

               -  Understand the need to commence the study treatment as soon as study drug is
                  dispensed following a negative pregnancy test

               -  Understand the need and accept to undergo pregnancy testing based on the
                  frequency outlined in this protocol

               -  Agree to abstain from breastfeeding during study participation

         10. Males must:

               -  Agree to use a latex condom during any sexual contact with females of
                  childbearing potential

               -  Agree to refrain from donating semen or sperm while on the study drugs and should
                  seek for sperm cryopreservation before therapy is started and should not father a
                  child while treated and during one year after end of study treatment

         11. Females of non-childbearing potential:

        Exclusion Criteria:

        Subjects are to be excluded from the study if they display any of the following criteria:

          1. Pregnant females; lactating women must end breast feeding before start of study
             treatment

          2. Serious accompanying disorder or impaired organ function

          3. Central nervous system (CNS) involvement of lymphoma - to be examined in case of
             clinical symptoms

          4. History of severe cardiac diseases, and cardiac function impairment

          5. Severe kidney disease

          6. HIV-positivity

          7. Hepatitis B and C as defined by seropositivity

          8. Patients under legal guardianship regarding medical decisions

          9. Ongoing treatment or study procedures within any other clinical trial with the
             exception of follow up

         10. Ongoing exclusion periods of other clinical studies after end of treatment

         11. In patients tested: Metabolic Computer tomography (CR) in a positron emission
             tomography-Computer tomography (PET-CT) scan after the last cycle of therapy prior to
             planned SCT

         12. Subjects with known hypersensitivity to the study drugs

         13. Criteria which in the opinion of the investigator precluded participation for
             scientific reasons, for reasons of compliance, or for reasons of the subject's safety

         14. Commitment to an institution by virtue of an order issued either by the judicial or
             the administrative authorities

         15. Dependency on the sponsor, trial site or investigator

         16. Additional exclusion criteria with respect to summary of product characteristics
             (SmPC) of the investigational medical product (IMPs) fludarabine, thiotepa,
             cyclophosphamide:

               1. Known hypersensitivity to fludarabine, thiotepa, cyclophosphamide or one of their
                  metabolites

               2. Renal impairment

               3. Decompensated haemolytic anaemia

               4. Concurrent application of vital vaccines

               5. Cystitis

               6. Renal tract obstruction

               7. Active and uncontrolled infection

               8. Notice: myelosuppression and impaired hematopoietic function is not an exclusion
                  criterion as this usual contraindication to the application to any of the IMPs
                  will be overcome by the stem cell transplantation following conditioning therapy.

                  -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertram Glass, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helios Klinikum Berlin-Buch</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katrin Linke, Dr.</last_name>
    <phone>: +49 (0) 351 25933 176</phone>
    <email>Katrin.linke@gwtonline.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carsta Köhler, Dr.</last_name>
    <phone>+ +49 (0) 351 25933 190</phone>
    <email>'bertram.glass@helios-gesundheit.de'</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HELIOS Klinik Berlin-Buch, Klinik für Hämatologie und Stammzelltransplantation</name>
      <address>
        <city>Berlin</city>
        <state>Brandenburg</state>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertram Glaß, Prof. Dr.</last_name>
      <phone>+ 49 (0) 30 940 11 21 02</phone>
      <email>'bertram.glass@helios-gesundheit.de'</email>
    </contact>
    <investigator>
      <last_name>Bertram Glaß</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg, Medizinische Klinik II</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christoph Schmid, Dr.</last_name>
      <phone>+ 49 (0) 821 / 400 37 15</phone>
      <email>christoph.schmid@klinikum-augsburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Christoph Schmid, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinisches Universitätsklinikum</name>
      <address>
        <city>Bochum</city>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland Schroers</last_name>
      <email>roland.schroers@rub.de</email>
    </contact>
    <investigator>
      <last_name>Roland Schroers, Prof.Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz gGmbH</name>
      <address>
        <city>Chemnitz</city>
        <zip>09116</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathias Hänel, Dr.</last_name>
      <email>m.haenel@skc.de</email>
    </contact>
    <investigator>
      <last_name>Mathias Hänel, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus Dresden, Medzinische Klinik I</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Friedrich Stölzel, Dr.</last_name>
      <phone>+ 49 (0) 351 45 8 25 83</phone>
    </contact>
    <investigator>
      <last_name>Friedrich Stölzel, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guido Kobbe, Prof.Dr.</last_name>
      <email>Kobbe@med.uni-duesseldorf.de</email>
    </contact>
    <investigator>
      <last_name>Guido Kobbe, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen Klinik für Hämatologie/Med. Onkologie</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin Hasenkamp, Dr.</last_name>
      <phone>+49 (0) 5513914289</phone>
      <email>justin.hasenkamp@med.uni-goettingen.de</email>
    </contact>
    <investigator>
      <last_name>Justin Hasenkamp, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lutz Müller, Dr.</last_name>
      <email>lutz.mueller@uk-halle.de</email>
    </contact>
    <investigator>
      <last_name>Lutz Müller, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf, Zentrum für Onkologie, Interdisziplinäre Klinik und Poliklinik für Stammzelltransplantation</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine Wolschke, Dr.</last_name>
      <phone>+ 49 (0) 40 / 741 05 81 25</phone>
      <email>wolschke@uke.de</email>
    </contact>
    <investigator>
      <last_name>Christine Wolschke, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg, Medizinische Klinik, Innere Medizin V</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Dreger, Prof. Dr.</last_name>
      <phone>+49 (0) 6221 / 56 82 83</phone>
      <email>peter.dreger@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Peter Dreger, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena, Klinik für Innere Medizin, Abtl. Hämatologie und Innternistische Onkologie</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inken Hilgendorf, Dr.</last_name>
      <phone>+49 (0)3641 / 932 46 64</phone>
    </contact>
    <investigator>
      <last_name>Inken Hilgendorf, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, KMT-Zentrum/ Med. Klinik A</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthias Stelljes, Prof. Dr.</last_name>
      <phone>+ 49 (0) 251 / 835 28 01</phone>
      <email>matthias.stelljes@ukmuenster.de</email>
    </contact>
    <investigator>
      <last_name>Matthias Stelljes, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald Illerhaus, Prof.Dr.</last_name>
      <email>g.illerhaus@klinikum-stuttgart.de</email>
    </contact>
    <investigator>
      <last_name>Gerald Illerhaus, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 31, 2019</study_first_submitted>
  <study_first_submitted_qc>October 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2019</study_first_posted>
  <last_update_submitted>October 8, 2019</last_update_submitted>
  <last_update_submitted_qc>October 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

